These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29535822)

  • 1. The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
    Dong J; Park SY; Nguyen N; Ezhilarasan R; Martinez-Ledesma E; Wu S; Henry V; Piao Y; Tiao N; Brunell D; Stephan C; Verhaak R; Sulman E; Balasubramaniyan V; de Groot JF
    Oncotarget; 2018 Feb; 9(12):10497-10509. PubMed ID: 29535822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma.
    Pandey A; Tripathi SC; Mai J; Hanash SM; Shen H; Mitra S; Rostomily RC
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
    Van den Bossche J; Domen A; Peeters M; Deben C; De Pauw I; Jacobs J; De Bruycker S; Specenier P; Pauwels P; Vermorken JB; Lardon F; Wouters A
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
    Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
    Hong M; Ren M; Silva J; Kennedy T; Choi J; Cowell JK; Hao Z
    Am J Cancer Res; 2014; 4(2):135-47. PubMed ID: 24660103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
    Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
    Li L; Xue W; Shen Z; Liu J; Hu M; Cheng Z; Wang Y; Chen Y; Chang H; Liu Y; Liu B; Zhao J
    Mol Ther Oncolytics; 2020 Sep; 18():215-225. PubMed ID: 32728610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volasertib suppresses the growth of human hepatocellular carcinoma
    Zheng DW; Xue YQ; Li Y; Di JM; Qiu JG; Zhang WJ; Jiang QW; Yang Y; Chen Y; Wei MN; Huang JR; Wang K; Wei X; Shi Z
    Am J Cancer Res; 2016; 6(11):2476-2488. PubMed ID: 27904765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
    Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
    Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
    Gjertsen BT; Schöffski P
    Leukemia; 2015 Jan; 29(1):11-9. PubMed ID: 25027517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
    Goroshchuk O; Kolosenko I; Kunold E; Vidarsdottir L; Pirmoradian M; Azimi A; Jafari R; Palm-Apergi C
    FASEB J; 2021 Jul; 35(7):e21741. PubMed ID: 34143546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.